2. Search Result
Search Result
Results for "

β1-integrin

" in MedChemExpress (MCE) Product Catalog:

31

Inhibitors & Agonists

2

Biochemical Assay Reagents

8

Peptides

2

Inhibitory Antibodies

2

Natural
Products

9

Recombinant Proteins

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13306
    Pyrintegrin
    4 Publications Verification

    		 Integrin Metabolic Disease
    Pyrintegrin is an β1-integrin agonist and a 2,4-disubstituted pyrimidine that promotes embryonic stem cells survival. Pyrintegrin enhances cell-extracellular matrix (ECM) adhesion-mediated integrin signaling. Pyrintegrin can be used as a podocyte-protective agent and has robustly adipogenic [1] .
    Pyrintegrin
  • HY-48959
    α7β1 integrin modulator-1

    		Integrin Metabolic Disease
    α7β1 integrin modulator-1 is a potent α7β1 integrin modulator. α7β1 integrin modulator-1 has the potential for the research of muscular dystrophy [1].
    α7β1 integrin modulator-1
  • HY-139702
    α5β1 integrin agonist-1

    		Integrin Cancer
    α5β1 integrin agonist-1, acting as α5β1 integrin agonist, is able to selectively deliver 5-FU into tumor cells, successfully leading to cancer cell death.
    α5β1 integrin agonist-1
  • HY-100506
    GLPG0187
    Maximum Cited Publications
    13 Publications Verification

    		 Integrin Cancer
    GLPG0187 is a broad spectrum integrin receptor antagonist with antitumor activity; inhibits αvβ1-integrin with an IC50 of 1.3 nM [1]. GLPG0187 inhibits migrasome biogenesis without cytotoxicity .
    GLPG0187
  • HY-P5812
    IDR 1002

    		Integrin Inflammation/Immunology
    IDR-1002 is an anti-infective peptide that enhances the ability of human monocytes to migrate toward chemokines on fibronectin. IDR-1002 also induces adhesion and activation of β1-integrin, a mechanism that promotes monocyte recruitment [1].
    IDR 1002
  • HY-P1868A
    α2β1 Integrin Ligand Peptide TFA
    2 Publications Verification

    DGEA peptide TFA

    		 Integrin Others
    α2β1 Integrin Ligand Peptide TFA interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. It is a potential antagonist of collagen receptors [1].
    α2β1 Integrin Ligand Peptide TFA
  • HY-134130
    Integrin modulator 1

    		Integrin Inflammation/Immunology
    Integrin modulator 1 is a potent and selective α4β1 integrin agonist, with an IC50 of 9.8 nM for RGD-binding α4β1. Integrin modulator 1 increases cell adhesion mediated by α4β1 integrin, with an EC50 of 12.9 nM [1].
    Integrin modulator 1
  • HY-111413A
    c(phg-isoDGR-(NMe)k) TFA

    		Integrin Cancer
    c(phg-isoDGR-(NMe)k) TFA is a selective and potent α5β1-integrin ligand with an IC50 of 2.9 nM [1].
    c(phg-isoDGR-(NMe)k) TFA
  • HY-P1868
    α2β1 Integrin Ligand Peptide

    DGEA peptide

    		 Integrin Infection
    α2β1 Integrin Ligand Peptide interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. It is a potential antagonist of collagen receptors [1].
    α2β1 Integrin Ligand Peptide
  • HY-111413
    c(phg-isoDGR-(NMe)k)

    		Integrin Cancer
    c(phg-isoDGR-(NMe)k) is a selective and potent α5β1-integrin ligand with an IC50 of 2.9 nM [1].
    c(phg-isoDGR-(NMe)k)
  • HY-P2267
    LDV
    1 Publications Verification

    		 Integrin Others
    LDV is a non-fluorescent analog of LDV-FITC. LDV is a α4β1 integrin (VLA-4) ligand, and binds α4β1 integrin in leukemia cells [1] .
    LDV
  • HY-136214
    R-BC154 acetate

    		Integrin Inflammation/Immunology Cancer
    R-BC154 acetate is a selective fluorescent α9β1 integrin antagonist. R-BC154 acetate acts as a useful high affinity, activation dependent integrin probe, which can be used to investigate α9β1 and α4β1 integrin binding activity [1].
    R-BC154 acetate
  • HY-P5038
    Cyclo(Gly-Arg-Gly-Asp-Ser-Pro)

    c(GRGDSP)

    		 Integrin Cancer
    Cyclo(Gly-Arg-Gly-Asp-Ser-Pro) (c(GRGDSP)) is an RGD-containing inhibitory peptide. Cyclo(Gly-Arg-Gly-Asp-Ser-Pro) is a synthetic α5β1 integrin ligand that competitively inhibits the binding of invasin (Inv) to α5β1 integrin expressed on Caco-2 cells [1].
    Cyclo(Gly-Arg-Gly-Asp-Ser-Pro)
  • HY-164768
    LT25

    		Integrin Cancer
    LT25 (compound 17) is a agonist of α5β1 integrin with EC50 value of 9.9 nM [1].
    LT25
  • HY-P1188
    LDV-FITC

    		Integrin Cancer
    LDV-FITC, a fluorescent peptide, is a FITC-conjugated LDV peptide (HY-P2267). LDV-FITC binds to the α4β1 integrin with high affinity (Kd: 0.3 nM and 12 nM for binding to U937 cells in the presence and absence of Mn 2+ respectively). LDV-FITC can be used to detect α4β1 integrin affinity [1] .
    LDV-FITC
  • HY-P1188A
    LDV-FITC TFA

    		Integrin Cancer
    LDV-FITC TFA, a fluorescent peptide, is a FITC-conjugated LDV peptide (HY-P2267). LDV-FITC TFA binds to the α4β1 integrin with high affinity (Kd: 0.3 nM and 12 nM for binding to U937 cells in the presence and absence of Mn 2+ respectively). LDV-FITC TFA can be used to detect α4β1 integrin affinity [1] .
    LDV-FITC TFA
  • HY-150124
    K34c

    		Integrin Cancer
    K34c is a potent and selective α5β1 integrin antagonist. K34c can be used for glioblastoma research [1].
    K34c
  • HY-108831
    Natalizumab
    2 Publications Verification

    		 Integrin Inflammation/Immunology Cancer
    Natalizumab is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses [1].
    Natalizumab
  • HY-P5929
    VnP-16

    		Integrin FAK Inflammation/Immunology
    VnP-16 can promote bone formation by accelerating osteoblast differentiation and activity through direct interaction with β1 integrin followed by FAK activation [1].
    VnP-16
  • HY-108831A
    Natalizumab (Solution)
    2 Publications Verification

    		 Integrin Inflammation/Immunology Cancer
    Natalizumab (Solution) is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses [1].
    Natalizumab (Solution)
  • HY-100445
    αvβ1 integrin-IN-1
    5 Publications Verification

    		 Integrin Cardiovascular Disease Cancer
    αvβ1 integrin-IN-1 (Compound C8) is a potent and selective αvβ1 integrin inhibitor with an IC50 of 0.63 nM. Antifibrotic effects [1].
    αvβ1 integrin-IN-1
  • HY-123802
    BIO7662

    		Integrin Cancer
    BIO7662 is a specific α4β1 antagonist. BIO7662 can be used to study α4β1 integrin-ligand interactions [1] .
    BIO7662
  • HY-100445A
    αvβ1 integrin-IN-1 TFA
    5 Publications Verification

    		 Integrin Cardiovascular Disease Cancer
    αvβ1 integrin-IN-1 TFA (Compound C8) is a potent and selective αvβ1 integrin inhibitor with an IC50 of 0.63 nM. Antifibrotic effects [1].
    αvβ1 integrin-IN-1 TFA
  • HY-161730
    αvβ1 integrin-IN-3

    		Integrin Cardiovascular Disease Cancer
    αvβ1 integrin-IN-3 is a selective αvβ1 integrin inhibitor. αvβ1 integrin-IN-3 has an antifibrotic effect [1].
    αvβ1 integrin-IN-3
  • HY-N2587
    Irigenin

    		Integrin Apoptosis Cancer
    Irigenin is a is a lead compound, and mediates its anti-metastatic effect by specifically and selectively blocking α9β1 and α4β1 integrins binding sites on C-C loop of Extra Domain A (EDA). Irigenin shows anti-cancer properties. It sensitizes TRAIL-induced apoptosis via enhancing pro-apoptotic molecules in gastric cancer cells [1].
    Irigenin
  • HY-15770
    TR-14035
    4 Publications Verification

    		 Integrin Inflammation/Immunology
    TR-14035 is a orally active dual α4β7/α4β1 integrin antagonist, with IC50 s of 7 nM and 87 nM for α4β7 and α4β1, respectively. TR-14035 can be used for the research of inflammation and autoimmune diseases [1] .
    TR-14035
  • HY-N2587R
    Irigenin (Standard)

    		Integrin Apoptosis Cancer
    Irigenin (Standard) is the analytical standard of Irigenin. This product is intended for research and analytical applications. Irigenin is a is a lead compound, and mediates its anti-metastatic effect by specifically and selectively blocking α9β1 and α4β1 integrins binding sites on C-C loop of Extra Domain A (EDA). Irigenin shows anti-cancer properties. It sensitizes TRAIL-induced apoptosis via enhancing pro-apoptotic molecules in gastric cancer cells [1].
    Irigenin (Standard)
  • HY-112055
    DIM-C-pPhOH
    5 Publications Verification

    		 Nuclear Hormone Receptor 4A/NR4A Apoptosis Cancer
    DIM-C-pPhOH is a nuclear receptor 4A1 (NR4A1) antagonist. DIM-C-pPhOH inhibits cancer cell growth and mTOR signaling, induce apoptosis and cellular stress. DIM-C-pPhOH reduces cell proliferation with IC50 values of 13.6 μM and 13.0 μM for ACHN cells and 786-O cells, respectively [1].
    DIM-C-pPhOH
  • HY-137561
    Bexotegrast

    PLN-74809

    		 Integrin Inflammation/Immunology
    Bexotegrast (PLN-74809) is an orally active, potent dual αvβ6/αvβ1 integrin inhibitor with Kd of 5.7 nM and 3.4 nM, respectively. Bexotegrast inhibits αvβ6- and αvβ1-induced TGF-β activation with IC50 values of 29.8 nM and 19.2 nM, respectively. Bexotegrast has antifibrogenic effects and block multiple avenues of TGF-β activation in the fibrotic lung [1] .
    Bexotegrast
  • HY-129453
    BOP sodium

    		Integrin Inflammation/Immunology
    BOP sodium is a potent and selective dual α9β1/α4β1 integrin inhibitor with Kd values in the picomolar range. BOP sodium shows the rapid and preferential mobilization of hematopoietic stem cell (HSC) and progenitors. BOP sodium has little inhibitory activity on α4β7, α1β1, α2β1, and α5β1, αIIBβ3 integrins [1] .
    BOP sodium
  • HY-122585
    proMMP-9 inhibitor-3c

    		MMP Src FAK Cancer
    proMMP-9 inhibitor-3c (compound 3c) is a potent proMMP-9 inhibitor. proMMP-9 inhibitor-3c is specific for binding to the proMMP-9 hemopexin-like domain (Kd=320 nM). proMMP-9 inhibitor-3c disruption of MMP-9 homodimerization prevents association of proMMP-9 with both α4β1 integrin and CD44 and results in the dissociation of EGFR. This disruption results in decreased phosphorylation of Src and its downstream target proteins focal adhesion kinase (FAK) and paxillin (PAX) [1].
    proMMP-9 inhibitor-3c

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: